Home/ Stocks/ FENC

Fennec Pharmaceuticals Inc. Common Stock

FENC XNAS

$6.02 -1.43 (-19.19%) ▼ 15-min delayed

Open

$6.79

High

$6.97

Low

$5.90

Volume

809.2K

Market Cap

$254.44M

About Fennec Pharmaceuticals Inc. Common Stock

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 32 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$12.46M	$-638,000	$-0.02
Q2 2025	$9.65M	$-3,152,000	$-0.11
Q1 2025	$8.75M	$-1,165,000	$-0.04
FY 2024	$47.54M	$-436,000	$-0.02

Earnings & Analyst Ratings

Next Earnings: Mon, May 11, 2026

Calendar →

Related Market News

No specific coverage for FENC yet. Check out our latest market news or earnings calendar.

Get FENC Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Fennec Pharmaceuticals Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.